STAR Mapping™
Rhythm AI is a medical software development company creating innovative solutions in 3D cardiac mapping to assist physicians in the management of patients with cardiac arrhythmia. Our initial focus has been on the successful development of new ways to locate the areas within the heart that may be responsible for the most common heart rhythm disorder: atrial fibrillation (AF).
Persistent AF Explained
Atrial fibrillation (AF) is a type of heart disorder marked by an irregular or rapid heartbeat. Persistent AF is one of three main types of the condition. In persistent AF, symptoms may last longer than seven days, and your heart’s rhythm is unable to regulate itself. Symptoms include:
Heart palpitations
Racing heartbeat
Dizziness or light-headedness
Fatigue
Overall weakness
Shortness of breath
Symptoms may appear on the first day that an individual experiences AF but may not realise that it is caused by AF. When the symptoms become more persistent (experiencing AF consecutively for seven days or more), AF may become more difficult to treat. In some patients AF can also be asymptomatic, which means the patient is not experiencing any symptoms and, in this scenario, ablation treatment is not recommended, unless they have associated problems like heart failure.
Treatment
Ablation, also known as catheter ablation, is a treatment that aims to control or correct certain types of abnormal heart rhythms.
STAR Mapping™
STAR Mapping™ is an AI technology used in catheter ablation of AF that replicates the logical, deductive, process applied to electrical signals, which are collected by the cardiac catheters already used in the mapping procedure.
Evidence
STAR Mapping™ has been tested in patients undergoing catheter ablation. Clinical trials validated that STAR Mapping™ correctly identified abnormal rhythm mechanisms, reduced time spent on ablation and is able to analyse more data than a human observer.
Get Involved
RHYTHM AI is looking to collaborate with new and incumbent 3D mapping companies to demonstrate compatibility and to undertake feasibility studies.
CURRENT AF TREATMENT SUCCESS IS 40%
TREATMENT SUCCESS WITH STAR MAPPING IS 80%
THE PROPORTION OF ABNORMAL RHYTHM SITES IDENTIFIED BY STAR MAPPING THAT RESPONDED TO ABLATION WAS 88%
Mapping Persistent Atrial Fibrillation
Professor Richard Schilling (Professor of Cardiology, St Bartholomew’s Hospital, London, UK; Medical Director, Arrhythmia Alliance) spoke at the Heart Rhythm meeting about the challenges and unmet needs of mapping persistent atrial fibrillation and how mapping may be optimised to improve treatment selection and patient outcomes.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Latest Rhythm AI News
RHYTHM AI announces publication of successful STAR Mapping™ clinical outcome trial
RHYTHM AI announces publication of successful STAR Mapping™ clinical outcome trial that identified Atrial Fibrillation (AF) drivers in all study patients STAR Mapping guided ablation of [...]
RHYTHM AI Receives MHRA Approval to Initiate the ROCSTAR Clinical Trial with STAR Mapping System
RHYTHM AI Receives MHRA Approval to Initiate the ROCSTAR Clinical Trial with STAR Mapping™ System UK Multi-Centre Trial to Recruit 177 Patients in up to 15 [...]
RHYTHM AI Announces Clinical Trial Collaboration With Biosense Webster
RHYTHM AI Announces Clinical Trial Collaboration With Biosense Webster Companies to collaborate on multi-centre study of STAR Mapping™ to improve outcomes of persistent Atrial Fibrillation treatment [...]
“To significantly improve single procedure success in treatment of persistent AF through development of the STAR Mapping System™.”
Company Information
RHYTHM AI is founded on world-leading research from Barts Heart Centre, London, UK and focused on the $5bn Atrial Fibrillation (AF) market and is forecasted to be $18bn by 2026 (16% CAGR).
The lead product is the STAR Mapping System™ which proof of concept studies demonstrate improvements in the outcome of Ablation procedures in for patients with persistent AF. Rhythm AI holds an exclusive global licence to develop and commercialise STAR Mapping™.